Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2015

01-05-2015 | Epidemiology

Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer

Authors: D. Cragun, D. Bonner, J. Kim, M. R. Akbari, S. A. Narod, A. Gomez-Fuego, J. D. Garcia, S. T. Vadaparampil, Tuya Pal

Published in: Breast Cancer Research and Treatment | Issue 1/2015

Login to get access

Abstract

Concerns about the potential for genomic advances to increase health disparities have been raised. Thus, it is important to assess referral and uptake of genetic counseling (GC) and testing in minority populations at high risk for hereditary breast and ovarian cancer (HBOC). Black women diagnosed with invasive breast cancer ≤age 50 in 2009–2012 were recruited through the Florida State Cancer Registry 6–18 months following diagnosis and completed a baseline questionnaire. Summary statistics, Chi-square tests, and path modeling were conducted to examine which demographic and clinical variables were associated with referral and access to genetic services. Of the 440 participants, all met national criteria for GC, yet only 224 (51 %) were referred for or received GC and/or HBOC testing. Variables most strongly associated with healthcare provider referral for GC included having a college education (OR 2.1), diagnosis at or below age 45 (OR 2.0), and triple negative tumor receptor status (OR 1.7). The strongest association with receipt of GC and/or HBOC testing was healthcare provider referral (OR 7.9), followed by private health insurance at diagnosis (OR 2.8), and household income greater than $35,000 in the year prior to diagnosis (OR 2.0). Study findings suggest efforts are needed to improve genetic services access among a population-based sample of high-risk Black women. These results indicate that socioeconomic factors and physician referral patterns contribute to disparities in access to genetic services within this underserved minority population.
Literature
3.
go back to reference Filippini SE, Vega A (2013) Breast cancer genes: beyond BRCA1 and BRCA2. Front Biosci (Landmark Ed) 18:1358–1372CrossRef Filippini SE, Vega A (2013) Breast cancer genes: beyond BRCA1 and BRCA2. Front Biosci (Landmark Ed) 18:1358–1372CrossRef
5.
go back to reference Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71CrossRefPubMed
6.
go back to reference Wooster R, Bignell G, Jea Lancaster (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792CrossRefPubMed Wooster R, Bignell G, Jea Lancaster (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792CrossRefPubMed
7.
go back to reference Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822. doi:10.1093/jnci/djt095 CrossRefPubMed Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822. doi:10.​1093/​jnci/​djt095 CrossRefPubMed
8.
go back to reference Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130. doi:10.1086/375033 CrossRefPubMedCentralPubMed Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130. doi:10.​1086/​375033 CrossRefPubMedCentralPubMed
9.
go back to reference Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104(9):1384–1392. doi:10.1038/bjc.2011.120 CrossRefPubMedCentralPubMed Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104(9):1384–1392. doi:10.​1038/​bjc.​2011.​120 CrossRefPubMedCentralPubMed
10.
go back to reference Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol 4(10):578–590CrossRefPubMed Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol 4(10):578–590CrossRefPubMed
11.
go back to reference Narod SA, Offit K (2005) Prevention and management of hereditary breast cancer. J Clin Oncol 23(8):1656–1663CrossRefPubMed Narod SA, Offit K (2005) Prevention and management of hereditary breast cancer. J Clin Oncol 23(8):1656–1663CrossRefPubMed
12.
go back to reference American College of O, Gynecologists, Bulletins–Gynecology ACoP, Genetics ACo, Society of Gynecologic O (2009) ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113(4):957–966. doi:10.1097/AOG.0b013e3181a106d4 CrossRef American College of O, Gynecologists, Bulletins–Gynecology ACoP, Genetics ACo, Society of Gynecologic O (2009) ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113(4):957–966. doi:10.​1097/​AOG.​0b013e3181a106d4​ CrossRef
13.
go back to reference Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, Callif-Daley F, Grumet SC, Hunt KS, Nagy RS, McKinnon WC, Petrucelli NM, Bennett RL, Trepanier AM (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151–161. doi:10.1007/s10897-011-9462-x CrossRefPubMed Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, Callif-Daley F, Grumet SC, Hunt KS, Nagy RS, McKinnon WC, Petrucelli NM, Bennett RL, Trepanier AM (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151–161. doi:10.​1007/​s10897-011-9462-x CrossRefPubMed
15.
go back to reference Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K (2010) American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 28(5):893–901CrossRefPubMed Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K (2010) American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 28(5):893–901CrossRefPubMed
16.
go back to reference Wood ME, Kadlubek P, Pham TH, Wollins DS, Lu KH, Weitzel JN, Neuss MN, Hughes KS (2014) Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American society of clinical oncology quality oncology practice initiative. J Clin Oncol 32(8):824–829. doi:10.1200/jco.2013.51.4661 CrossRefPubMed Wood ME, Kadlubek P, Pham TH, Wollins DS, Lu KH, Weitzel JN, Neuss MN, Hughes KS (2014) Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American society of clinical oncology quality oncology practice initiative. J Clin Oncol 32(8):824–829. doi:10.​1200/​jco.​2013.​51.​4661 CrossRefPubMed
18.
go back to reference Armstrong K, Micco E, Carney A, Stopfer J, Putt M (2005) Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA 293(14):1729–1736CrossRefPubMed Armstrong K, Micco E, Carney A, Stopfer J, Putt M (2005) Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA 293(14):1729–1736CrossRefPubMed
21.
go back to reference Moyer VA (2013) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. preventive services task force recommendation statement. Ann Intern Med. doi:10.7326/m13-2747 Moyer VA (2013) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. preventive services task force recommendation statement. Ann Intern Med. doi:10.​7326/​m13-2747
22.
go back to reference Pal T, Rocchio E, Garcia A, Rivers D, Vadaparampil S (2011) Recruitment of black women for a study of inherited breast cancer using a cancer registry-based approach. Genet Test Mol Biomark 15(1–2):69–77. doi:10.1089/gtmb.2010.0098 CrossRef Pal T, Rocchio E, Garcia A, Rivers D, Vadaparampil S (2011) Recruitment of black women for a study of inherited breast cancer using a cancer registry-based approach. Genet Test Mol Biomark 15(1–2):69–77. doi:10.​1089/​gtmb.​2010.​0098 CrossRef
23.
go back to reference Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G (2012) Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors. J Cancer Epidemiol 2012:298745. doi:10.1155/2012/298745 CrossRefPubMedCentralPubMed Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G (2012) Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors. J Cancer Epidemiol 2012:298745. doi:10.​1155/​2012/​298745 CrossRefPubMedCentralPubMed
24.
go back to reference McCarthy AM, Bristol M, Fredricks T, Wilkins L, Roelfsema I, Liao K, Shea JA, Groeneveld P, Domchek SM, Armstrong K (2013) Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study. Cancer. doi:10.1002/cncr.28268 PubMedCentral McCarthy AM, Bristol M, Fredricks T, Wilkins L, Roelfsema I, Liao K, Shea JA, Groeneveld P, Domchek SM, Armstrong K (2013) Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study. Cancer. doi:10.​1002/​cncr.​28268 PubMedCentral
26.
go back to reference Matloff E, Caplan A (2008) Direct to confusion: lessons learned from marketing BRCA testing. Am J Bioeth 8(6):5–8CrossRefPubMed Matloff E, Caplan A (2008) Direct to confusion: lessons learned from marketing BRCA testing. Am J Bioeth 8(6):5–8CrossRefPubMed
27.
go back to reference Hull SC, Prasad K (2001) Reading between the lines: direct-to-consumer advertising of genetic testing in the USA. Reprod Health Matters 9(18):44–48CrossRefPubMed Hull SC, Prasad K (2001) Reading between the lines: direct-to-consumer advertising of genetic testing in the USA. Reprod Health Matters 9(18):44–48CrossRefPubMed
28.
go back to reference Radford C, Prince A, Lewis K, Pal T (2013) Factors which impact the delivery of genetic risk assessment services focused on inherited cancer genomics: expanding the role and reach of certified genetics professionals. J Genet Couns. doi:10.1007/s10897-013-9668-1 PubMed Radford C, Prince A, Lewis K, Pal T (2013) Factors which impact the delivery of genetic risk assessment services focused on inherited cancer genomics: expanding the role and reach of certified genetics professionals. J Genet Couns. doi:10.​1007/​s10897-013-9668-1 PubMed
29.
go back to reference Bowen DJ, Battuello KM, Raats M (2005) Marketing genetic tests: empowerment or snake oil? Health Educ Behav 32(5):676–685CrossRefPubMed Bowen DJ, Battuello KM, Raats M (2005) Marketing genetic tests: empowerment or snake oil? Health Educ Behav 32(5):676–685CrossRefPubMed
30.
go back to reference Hogarth S, Javitt G, Melzer D (2008) The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues. Annu Rev Genomics Hum Genet 9:161–182CrossRefPubMed Hogarth S, Javitt G, Melzer D (2008) The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues. Annu Rev Genomics Hum Genet 9:161–182CrossRefPubMed
31.
go back to reference Stuckey A, Febbraro T, Laprise J, Wilbur JS, Lopes V, Robison K (2014) Adherence patterns to national comprehensive cancer network guidelines for referral of women with breast cancer to genetics professionals. Am J Clin Oncol. doi:10.1097/COC.0000000000000073 PubMed Stuckey A, Febbraro T, Laprise J, Wilbur JS, Lopes V, Robison K (2014) Adherence patterns to national comprehensive cancer network guidelines for referral of women with breast cancer to genetics professionals. Am J Clin Oncol. doi:10.​1097/​COC.​0000000000000073​ PubMed
34.
go back to reference Bellcross CA, Leadbetter S, Alford SH, Peipins LA (2013) Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral. Cancer Epidemiol Biomark Prev 22(4):728–735. doi:10.1158/1055-9965.EPI-12-1280 CrossRef Bellcross CA, Leadbetter S, Alford SH, Peipins LA (2013) Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral. Cancer Epidemiol Biomark Prev 22(4):728–735. doi:10.​1158/​1055-9965.​EPI-12-1280 CrossRef
35.
go back to reference Thompson HS, Sussner K, Schwartz MD, Edwards T, Forman A, Jandorf L, Brown K, Bovbjerg DH, Valdimarsdottir HB (2012) Receipt of genetic counseling recommendations among black women at high risk for BRCA mutations. Genet Test Mol Biomark 16(11):1257–1262. doi:10.1089/gtmb.2012.0114 CrossRef Thompson HS, Sussner K, Schwartz MD, Edwards T, Forman A, Jandorf L, Brown K, Bovbjerg DH, Valdimarsdottir HB (2012) Receipt of genetic counseling recommendations among black women at high risk for BRCA mutations. Genet Test Mol Biomark 16(11):1257–1262. doi:10.​1089/​gtmb.​2012.​0114 CrossRef
Metadata
Title
Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer
Authors
D. Cragun
D. Bonner
J. Kim
M. R. Akbari
S. A. Narod
A. Gomez-Fuego
J. D. Garcia
S. T. Vadaparampil
Tuya Pal
Publication date
01-05-2015
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3374-7

Other articles of this Issue 1/2015

Breast Cancer Research and Treatment 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine